Recursion agrees all-stock takeover of Exscientia to combine AI drug-discovery platforms

8 Aug 2024Source: Recursion: Recursion and Exscientia enter definitive agreementAlso reported by Recursion Form 8-K on completion (SEC), Recursion (completion)

Recursion and Exscientia agreed on 8 August 2024 to combine, with Exscientia shareholders receiving 0.7729 Recursion shares per share and owning about 26% of the merged company. The companies cited about $850m of combined cash, around 10 clinical readouts expected within 18 months and roughly $100m a year in savings. The deal completed on 20 November 2024, when Exscientia became a Recursion subsidiary.

Why it matters

Investors and pharma partners in AI drug discovery dealt with one combined company holding about $850m in cash and expecting around 10 clinical readouts within 18 months.

When: 8 Aug 2024
ID: WTA-N-2024-0012
Where: United States, United Kingdom
Who: Recursion, Exscientia; Chris Gibson
Topics: Drug discovery, Investment and financing

Summary by wheresthe.ai, from Recursion and the reporting credited above. Checked against the source on 9 Oct 2026.

Read the original at Recursion

Source copy: download the page text as saved on 18 Oct 2026 (PDF). Also held by the Internet Archive.

Cite this story

WTA-N-2024-0012: “Recursion agrees all-stock takeover of Exscientia to combine AI drug-discovery platforms.” wheresthe.ai, 8 Aug 2024. https://wheresthe.ai/d/us-gb-recursion-exscientia-merger-2024-08/ (source: Recursion: Recursion and Exscientia enter definitive agreement).

Spotted an error? Email [email protected].